Wu Huan-lin, Wang Xia, Li Xin-mei, Luo Wen-jie, Deng Tie-tao
Heart Center, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.
Chin J Integr Med. 2005 Sep;11(3):173-8. doi: 10.1007/BF02836499.
To assess the efficacy of the Coronary Heart Disease (CHD) Capsules worked out by Prof. Deng --in improving quality of life of CHD patients of qi deficiency with phlegm and blood stasis syndrome.
According to the WHO's diagnosis criteria of CHD, a total of 93 stable angina patients were divided into 3 groups using the single blinded method. The groups were evenly distributed into CHD Capsule treated group (CHDC), isosorbide dinitrate control group (ID), and Compound Prescription Danshen Droplet Pills control group (CPDDP). Two courses of treatment lasting for 6 months were given. During the courses of treatment, the following parameters were observed: clinical symptoms of angina pectoris, ECG change, treadmill exercise test, 36 items in short form of health survey (SF-36) and Seattle Angina Questionnaire (SAQ) scale.
After 6 months of treatment, all the three groups showed good curative effect in angina pectoris, ECG and treadmill exercise test, differences between them had no statistical significance. The CHDC group showed a better result in nitro-glycerine stopping or alleviation rate and in improving symptoms than the other groups (P < 0.05). The general health, vitality, role-emotional, mental health and reported health transition in the CHDC group were significantly better than those in the control groups (P < 0.05). The scores in physiological functioning role, physiological function and pain alleviation were not different among the three groups.
Prof. DENG Tie-tao's CHDC is effective in treating CHD with qi deficiency, phlegm and blood stasis and also in improving the quality of life. CHDC is more suitable to be used in long-term treatment than isosorbide dinitrate. The SF-36 and SAQ can be used to appraise the curative effect of traditional Chinese medicine agents for CHD angina pectoris.
评估邓铁涛教授研制的冠心病胶囊对改善冠心病气虚痰瘀证患者生活质量的疗效。
按照世界卫生组织冠心病诊断标准，采用单盲法将93例稳定型心绞痛患者分为3组。各组患者平均分为冠心病胶囊治疗组（CHDC）、硝酸异山梨酯对照组（ID）和复方丹参滴丸对照组（CPDDP）。给予两个疗程的治疗，为期6个月。在治疗过程中，观察以下参数：心绞痛临床症状、心电图变化、平板运动试验、健康调查简表（SF-36）中的36项以及西雅图心绞痛问卷（SAQ）量表。
治疗6个月后，三组在心绞痛、心电图及平板运动试验方面均显示出良好疗效，组间差异无统计学意义。CHDC组在硝酸甘油停减率及症状改善方面优于其他两组（P<0.05）。CHDC组在总体健康、活力、角色情感、心理健康及健康自评转变方面显著优于对照组（P<0.05）。三组在生理功能角色、生理功能及疼痛缓解方面的得分无差异。
邓铁涛教授的CHDC治疗冠心病气虚痰瘀证有效，且能改善生活质量。与硝酸异山梨酯相比，CHDC更适合长期治疗。SF-36和SAQ可用于评估中药制剂治疗冠心病心绞痛的疗效。
